Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.735 USD | -8.23% | -14.73% | +84.90% |
04-29 | Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children | MT |
04-29 | Transcript : Aquestive Therapeutics, Inc. - Special Call |
Sales 2024 * | 50.21M 4B | Sales 2025 * | 57.98M 4.62B | Capitalization | 340M 27.11B |
---|---|---|---|---|---|
Net income 2024 * | -27M -2.15B | Net income 2025 * | -27M -2.15B | EV / Sales 2024 * | 6.37 x |
Net cash position 2024 * | 20.23M 1.61B | Net Debt 2025 * | 15.47M 1.23B | EV / Sales 2025 * | 6.13 x |
P/E ratio 2024 * |
-10.4
x | P/E ratio 2025 * |
-12.7
x | Employees | 135 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95% |
Latest transcript on Aquestive Therapeutics, Inc.
1 day | -8.23% | ||
1 week | -14.73% | ||
Current month | -12.32% | ||
1 month | -12.32% | ||
3 months | +51.83% | ||
6 months | +163.03% | ||
Current year | +84.90% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Barber
CEO | Chief Executive Officer | 48 | 30/06/07 |
A. Toth
DFI | Director of Finance/CFO | 65 | 30/12/20 |
Stephen Wargacki
CTO | Chief Tech/Sci/R&D Officer | 46 | 31/12/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 09/08/22 |
Santo Costa
CHM | Chairman | 78 | 30/11/15 |
Gregory Brown
BRD | Director/Board Member | 70 | 28/02/07 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 3.735 | -8.23% | 7,644,861 |
26/04/24 | 4.07 | +3.56% | 2,986,647 |
25/04/24 | 3.93 | +0.77% | 1,935,903 |
24/04/24 | 3.9 | -8.88% | 2,147,676 |
23/04/24 | 4.28 | -2.28% | 1,699,537 |
Delayed Quote Nasdaq, April 29, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+84.90% | 340M | |
+26.47% | 664B | |
+26.74% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.43% | 234B | |
+4.71% | 199B | |
-9.53% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- AQST Stock